Ramelteon : A novel hypnotic lacking abuse liability and sedative adverse effectsJOHNSON, Matthew W; SUESS, Patricia E; GRIFFITHS, Roland R et al.Archives of general psychiatry. 2006, Vol 63, Num 10, pp 1149-1157, issn 0003-990X, 9 p.Article

Ramelteon. CommentaryMCGECHAN, Adam; WELLINGTON, Keri; GRIFFITHS, Roland R et al.CNS drugs. 2005, Vol 19, Num 12, pp 1057-1067, issn 1172-7047, 11 p.Article

Tasimelteon: A Melatonin Receptor Agonist for Non-24-Hour Sleep-Wake DisorderJOHNSA, Jessica D; NEVILLE, Michael W.The Annals of pharmacotherapy. 2014, Vol 48, Num 12, pp 1636-1641, issn 1060-0280, 6 p.Article

Ramelteon for the treatment of insomniaBORJA, Nancy L; DANIEL, Karen L.Clinical therapeutics. 2006, Vol 28, Num 10, pp 1540-1555, issn 0149-2918, 16 p.Article

Ramelteon : A Novel Approach in the Treatment of InsomniaREYNOLDSON, Jill N; ELLIOTT, Ellie S. R; NELSON, Leigh Anne et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 9, pp 1262-1271, issn 1060-0280, 10 p.Article

Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep―wake cycle architectureDESCAMPS, Amandine; ROUSSET, Colette; MILLAN, Mark et al.Psychopharmacologia. 2009, Vol 205, Num 1, pp 93-106, issn 0033-3158, 14 p.Article

Melatonergic Drugs in Clinical PracticeHARDELAND, Rüdiger; POEGGELER, Burkhard; SRINIVASAN, Venkataramanujan et al.Arzneimittel-Forschung. 2008, Vol 58, Num 1, pp 1-10, issn 0004-4172, 10 p.Article

Ramelteon (Rozerem- USA) contre l'insomnie = Ramelteon for insomniaThe Medical letter on drugs and therapeutics (Edition française). 2005, Vol 27, Num 25, pp 135-137, issn 0253-8512, 3 p.Article

Efficacy and Safety of 6-Month Nightly Ramelteon Administration in Adults with Chronic Primary InsomniaMAYER, Geert; WANG-WEIGAND, Sherry; ROTH-SCHECHTER, Barbara et al.Sleep (New York, NY). 2009, Vol 32, Num 3, pp 351-360, issn 0161-8105, 10 p.Article

Melatonin agonists in primary insomnia and depression-associated insomnia: Are they superior to sedative-hypnotics?SRINIVASAN, Venkatramanujan; BRZEZINSKI, Amnon; PANDI-PERUMAL, Seithikurippu R et al.Progress in neuro-psychopharmacology & biological psychiatry. 2011, Vol 35, Num 4, pp 913-923, issn 0278-5846, 11 p.Article

Treatment of delirium with ramelteon: initial experience in three patientsKIMURA, Ryo; MORI, Kohji; KUMAZAKI, Hirokazu et al.General hospital psychiatry. 2011, Vol 33, Num 4, pp 407-409, issn 0163-8343, 3 p.Article

Placebo-Controlled Pilot Study of Ramelteon for Adiposity and Lipids in Patients With SchizophreniaBORBA, Christina P. C; XIAODUO FAN; COPELAND, Paul M et al.Journal of clinical psychopharmacology. 2011, Vol 31, Num 5, pp 653-658, issn 0271-0749, 6 p.Article

Effects of the Melatonin MT-1/MT-2 Agonist Ramelteon on Daytime Body Temperature and SleepMARKWALD, Rachel R; LEE-CHIONG, Teofilo L; BURKE, Tina M et al.Sleep (New York, NY). 2010, Vol 33, Num 6, pp 825-831, issn 0161-8105, 7 p.Article

Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta) : Dependence liability studiesFRANCE, Charles P; WELTMAN, Robert H; KOEK, Wouter et al.Behavioral neuroscience. 2006, Vol 120, Num 3, pp 535-541, issn 0735-7044, 7 p.Article

Synthesis of 4-aza analog of ramelteon: a novel tricyclic 1,6,7,8-tetrahydro-2H-cyclopenta[d]furo[2,3-b]pyridine derivative as melatonin receptor ligandKOIKE, Tatsuki; HOASHI, Yasutaka; TAKAI, Takafumi et al.Tetrahedron letters. 2011, Vol 52, Num 23, issn 0040-4039, 2924, 3009-3011 [4 p.]Article

Acute sleep-promoting action of the melatonin agonist, ramelteon, in the ratFISHER, Simon P; DAVIDSON, Kathryn; KULLA, Alexander et al.Journal of pineal research. 2008, Vol 45, Num 2, pp 125-132, issn 0742-3098, 8 p.Article

Pharmacology of Ramelteon, a Selective MT₁/MT₂ Receptor Agonist : A Novel Therapeutic Drug for Sleep DisordersMIYAMOTO, Masaomi.CNS neuroscience & therapeutics (Print). 2009, Vol 15, Num 1, pp 32-51, issn 1755-5930, 20 p.Article

rameltéon : INSOMNIE : NON AUX PLACEBOS À RISQUE = Ramelteon for insomnia : a critical studyLa Revue Prescrire. 2008, Vol 28, Num 296, pp 406-408, issn 0247-7750, 3 p.Article

A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbanceMCELROY, Susan L; WINSTANLEY, Erin L; MARTENS, Brian et al.International clinical psychopharmacology. 2011, Vol 26, Num 1, pp 48-53, issn 0268-1315, 6 p.Article

The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary diseaseKRYGER, Meir; ROTH, Thomas; WANG-WEIGAND, Sherry et al.Sleep & breathing. 2009, Vol 13, Num 1, pp 79-84, issn 1520-9512, 6 p.Article

Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in ratMATHES, Alexander M; KUBULUS, Darius; WAIBEL, Lina et al.Critical care medicine. 2008, Vol 36, Num 10, pp 2863-2870, issn 0090-3493, 8 p.Article

Ramelteon 8 mg/d Versus Placebo in Patients with Chronic Insomnia : Post Hoc Analysis of a 5-Week Trial Using 50% or Greater Reduction in Latency to Persistent Sleep as a Measure of Treatment EffectMINI, Louis; WANG-WEIGAND, Sherry; ZHANG, Jeff et al.Clinical therapeutics. 2008, Vol 30, Num 7, pp 1316-1323, issn 0149-2918, 8 p.Article

Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cellsIMBESI, Marta; UZ, Tolga; DZITOYEVA, Svetlana et al.Neuroscience letters. 2008, Vol 439, Num 1, pp 34-36, issn 0304-3940, 3 p.Article

Effect of ramelteon (TAK-375), a selective MT₁/MT₂ receptor agonist, on motor performance in miceMIYAMOTO, Masaomi.Neuroscience letters. 2006, Vol 402, Num 3, pp 201-204, issn 0304-3940, 4 p.Article

MELATONIN RECEPTOR AGONIST RAMELTEON ACTIVATES THE EXTRACELLULAR SIGNAL-REGULATED KINASE 1/2 IN MOUSE CEREBELLAR GRANULE CELLSIMBESI, M; UZ, T; MANEV, H et al.Neuroscience. 2008, Vol 155, Num 4, pp 1160-1164, issn 0306-4522, 5 p.Article